Ketoamide inhibitors in chronic nerve disease

Details Ketoamide inhibitors in chronic nerve disease Ketoamide inhibitors in chronic nerve disease

2003-09-25

2008-09-30

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000

Reexamination Certificate

active

07429560

ABSTRACT:
Compositions and methods for treating neural pathologies are provided. In particular, compositions and methods for treating neural pathologies including axonal degeneration are provided. The compositions include peptide α-ketomides optionally in combination with a second therapeutic agent. Another aspect of the invention provides compositions and methods for treating hyperproliferative disorders. Exemplary compositions for treating hyperproliferative disorders include an anti-proliferative agent such as paclitaxel, in combination with a calpain inhibitor such as AK295.

REFERENCES:
patent: 5514694 (1996-05-01), Powers et al.
patent: 5554767 (1996-09-01), Want et al.
patent: 5610297 (1997-03-01), Powers
patent: 5650508 (1997-07-01), Powers
patent: 5760048 (1998-06-01), Wang et al.
patent: 6235929 (2001-05-01), Powers
Molla A., et al., “Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors,” Aug. 1993 J Virology 67(8): 4688-4695.
Wang et al. “Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy.” J Neuropathol Exp Neurol., 2000, 59(7), 599-606.
Schaecher et al. “Mechanism of myelin breakdown in experimental demyelination: a putative role for calpain.” Neurochem. Res., 2001, 26, 731-737.
Dourdin et al.Reduced Cell Migration and Disruption of the Actin Cytoskeleton in Calpain-deficient Embryonic Fibroblasts. The Journal of Biological Chemistry, Dec. 21, 2001, vol. 276, No. 51, pp. 48382-48388.
Kohli et al.Calpain is a mediator of preservation-reperfusion injury in rat liver transplantation. Proc. Natl. Acad. Sci. USA, Medical Sciences, Aug. 1997, vol. 94, pp. 9354-9359.
Kupina et al.The Novel Calpain Inhibitor SJA6017 Improves Functional Outcome after Delayed Administration in a Mouse Model of Diffuse Brain Injury. Journal of Neurotrauma, 2001, vol. 18, No. 11, pp. 1229-1240.
Markgraf et al.Six-hour Window of Opportunity for Calpain Inhibition in Focal Cerebral Ischemia in Rats. American Heart Association, Inc., 1998, pp. 152-158.
Saatman et al.,Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc. Natl. Acad. Sci. USA, Neurobiology, Apr. 1996, vol. 93, pp. 3428-3433.
Schumacher et al.Pretreatment with Calpain Inhibitor CEP-4143 Inhibits Calpain I Activiation and Cytoskeletal Degradation, Improves Neurological Function, and Enhances Axonal Survival After Traumatic Spinal Cord Injury. Journal of Neurochemistry, vol. 74, No. 4, pp. 1646-1655, 2000.
Shields et al.A punative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc. Natl. Acad. Sci. USA, Sep. 1999, vol. 96, pp. 11486-11491.

Affiliated with

Also associated with

Rating

Ketoamide inhibitors in chronic nerve disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ketoamide inhibitors in chronic nerve disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ketoamide inhibitors in chronic nerve disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3985603